BOULDER, Colo. and PORTLAND, Ore., Jan. 20, 2012 — Boulder Diagnostics Inc. and Portland State University (PSU) announced today the entry into a license and collaboration agreement to develop rapid diagnostic tests for homocysteine and related compounds based on a highly specific dye technology developed at PSU. Under the agreement Boulder will finance further research at the Department of Chemistry, and PSU will be entitled to royalties on future sales of the licensed technology. Further details were not disclosed.
The innovative and highly specific dye technology developed in the laboratory of Prof. Robert Strongin at PSU enables the development of rapid diagnostic tests for homocysteine and related compounds. The new dye technology will be used in medical tests to help determine indicators for a variety of diseases, including cancer, Alzheimer’s, Parkinson’s, cystic fibrosis, and HIV.
“The groundbreaking technology of Prof. Strongin and his team can form the basis for a new line of products,” says Wolfgang Pieken, CEO of Boulder Diagnostics Inc.
“We are excited to adapt our innovative detection chemistry to rapid diagnostic tests with Boulder Diagnostics,” comments Robert Strongin, Professor of Chemistry at Portland State University.
For further information, please contact:
About Boulder Diagnostics
Boulder Diagnostics Inc. provides new diagnostic solutions to undeserved or underperforming disease diagnostics areas. It currently markets novel specific antibody reagents for the diagnosis of parasite infections.
About Portland State University (PSU)
Located in Portland, Oregon, PSU has about 30,000 undergraduate and graduate students. PSU’s motto is “Let Knowledge Serve the City,” and it provides every student with opportunities to work with businesses, schools and organizations on real-world projects. Its downtown campus exhibits PSU’s commitment to sustainability through green buildings and business practice. Sustainability is incorporated into much of PSU’s curriculum.
# # #